Tiziana Life Sciences is a biotechnology company that is focused on the discovery and development of molecules to treat unmet medical needs in oncology and immunology. Co.'s main product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody (mAb) in clinical development. MAbs represent a single pure antibody produced by single clones and are a class of human therapeutics for treating cancers and autoimmune diseases. Co.'s main product candidate in oncology is Milciclib (TZLS-201), which is an orally bioavailable, small molecule spectrum inhibitor of cyclin-dependent kinases, and Src family kinases. We show 2 historical shares outstanding datapoints in our TLSA shares outstanding history coverage, used to compute TLSA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TLSA market cap history over the course of time is important for investors
interested in comparing TLSA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TLSA versus a peer is one thing; comparing
TLSA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TLSA can fluctuate over the course of history.
With this page we aim to empower investors researching TLSA by allowing them to research the TLSA market cap history. |
Free TLSA Email Alerts:
Video: The Importance of Market Cap
